W
Wan-Jen Hong
Researcher at Genentech
Publications - 34
Citations - 1684
Wan-Jen Hong is an academic researcher from Genentech. The author has contributed to research in topics: Venetoclax & Myeloid leukemia. The author has an hindex of 12, co-authored 34 publications receiving 718 citations.
Papers
More filters
Journal ArticleDOI
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D. DiNardo,Brian A. Jonas,Vinod Pullarkat,Michael J. Thirman,Jacqueline S. Garcia,Andrew H. Wei,Marina Konopleva,Hartmut Döhner,Anthony Letai,Pierre Fenaux,Elizabeth A. Koller,Violaine Havelange,Brian Leber,Jordi Esteve,Jianxiang Wang,Vlatko Pejša,Roman Hájek,Kimmo Porkka,Árpád Illés,David Lavie,Roberto M. Lemoli,Kazuhito Yamamoto,Sung-Soo Yoon,Jun-Ho Jang,Su-Peng Yeh,Mehmet Turgut,Wan-Jen Hong,Ying Zhou,Jalaja Potluri,Keith W. Pratz +29 more
TL;DR: In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.
Journal ArticleDOI
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Amer M. Zeidan,Daniel A. Pollyea,Jacqueline S. Garcia,Andrew M. Brunner,Fernando Roncolato,Uma Borate,Olatoyosi Odenike,Ashish Bajel,Anne Marie Watson,Katharina Götze,Florian Nolte,Peter Tan,Wan-Jen Hong,Martin Dunbar,Ying Zhou,Lori A. Gressick,William Ainsworth,Jason Harb,Ahmed Salem,John Hayslip,Ronan Swords,Guillermo Garcia-Manero +21 more
TL;DR: Venetoclax (Ven), a selective, potent, orally bioavailable BCL-2 inhibitor, was recently approved in combination with HMAs or low dose cytarabine for the frontline management of older unfit pts with AML to evaluate the safety and efficacy of Ven in pts with R/R MDS.
Journal ArticleDOI
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Jonathan L. Kaufman,Cristina Gasparetto,Fredrik Schjesvold,Philippe Moreau,Cyrille Touzeau,Thierry Facon,Lawrence H. Boise,Yanwen Jiang,Xiaoqing Yang,Fengjiao Dunbar,Deeksha Vishwamitra,Stefanie Unger,R. N. Tammy Macartney,John Pesko,Yao Yu,Ahmed Salem,Jeremy A. Ross,Wan-Jen Hong,Paulo Maciag,James M. Pauff,Shaji Kumar +20 more
TL;DR: Venetoclax (Ven) is a selective small-molecule inhibitor of BCL-2 that exhibits antitumoral activity against MM cells with t(11;14) translocation as discussed by the authors.
Journal ArticleDOI
Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
Jacqueline S. Garcia,Andrew H. Wei,Uma Borate,Chun Yew Fong,Maria R. Baer,Florian Nolte,Joseph G. Jurcic,Meagan A. Jacoby,Wan-Jen Hong,Uwe Platzbecker,Olatoyosi Odenike,Ilona Cunningham,Ying Zhou,Bo Tong,Leah Hogdal,Rajesh Kamalakar,Jessica E. Hutti,Steve Kye,Guillermo Garcia-Manero +18 more
TL;DR: The primary objectives of the study were to assess the Ven+Aza safety profile and to establish the RP2D, and PROs were exploratory and included the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) scale.
Journal ArticleDOI
Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML
Naval Daver,Daniel A. Pollyea,Karen W.L. Yee,Pierre Fenaux,Joseph Brandwein,Norbert Vey,Giovanni Martinelli,Kevin R. Kelly,Gail J. Roboz,Jacqueline S. Garcia,Arnaud Pigneux,Smita Kshirsagar,Monique Dail,Jue Wang,Mehrdad Mobasher,Lin-Chi Chen,Wan-Jen Hong,Marina Konopleva,Michael Andreeff +18 more
TL;DR: This is the first study evaluating novel-novel oral combinations with VEN in pts with R/R AML and preliminary PK analyses suggest that VEN exposure is slightly lower than expected, while cobi and idasa efficacy is suggested to be slightly better than expected.